Compare AstraZeneca plc (AZN) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Hormel Foods Corp — how do they compare? AstraZeneca plc trades at $167.14 (market cap $253.13B), while Hormel Foods Corp trades at $24.92 (market cap $13.65B). The key difference: AstraZeneca plc is far larger — about 18.5× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| AZN | HRL | |
|---|---|---|
Market Cap | $253.13B | $13.65B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $29.91 |
52-Week Low | $137.44 | $19.74 |
Enterprise Value | $279.37B | $15.65B |
Dividend Yield | 1.92% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Hormel Foods (HRL) trades at $24.46, down 1.11% on the day, with a neutral technical outlook and mixed analyst sentiment. The company has beaten earnings estimates for three consecutive quarters, though net income margin has compressed to 3.82% in 2025 from 6.75% in 2024. Recent strategic moves include the sale of its Brazilian Ceratti operations to focus on higher-growth markets, while maintaining its Dividend King status with 60 consecutive years of dividend increases.
The stock presents a value opportunity with a P/E of 28.78 and consensus price target of $26.33 (7.6% upside), but faces margin pressure from input cost inflation and competitive headwinds. The dividend yield of approximately 4.7% provides income support, though earnings stabilization remains key for sustained recovery from multi-year lows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
